Menu

Acts on multiple pathways in the clotting cascade to facilitate coagulation in an in vitro analysis2

FEIBA acts on pathways in the clotting cascade to facilitate coagulation in an in vitro analysis

In Vitro Analysis

Multiple clotting factors of FEIBA achieved hemostasis in an in vitro analysis2

Factors II and Xa provided by FEIBA [Anti-Inhibitor Coagulant Complex] can overcome the impaired tenase complex formation.2

Multiple clotting factors of FEIBA
  • FEIBA contains additional factors that target multiple sites within the coagulation system. FEIBA contains mainly non-activated forms of factors II, IX, X, and mainly activated factor VII
  • Provides both FII (prothrombin) and FXa for thrombin generation
  • Peak thrombin generation at 15 to 30 minutes in an in vitro assay17
    • Thrombin generation returns to baseline value 8 to 12 hours after a single dose of FEIBA17

Selected Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.

CONTRAINDICATIONS

FEIBA is contraindicated in patients with:

  • History of anaphylactic or severe hypersensitivity reactions to FEIBA or any of its components, including factors of the kinin generating system
  • Disseminated intravascular coagulation (DIC)
  • Acute thrombosis or embolism (including myocardial infarction)

Manufacturing

FEIBA offers advanced plasma processing.

Learn More

Efficacy and Safety Data

Find out how FEIBA helped patients with hemophilia A or B with inhibitors in a clinical trial.

See the Data
See LessMore

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in
hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is not indicated for the treatment of bleeding episodes resulting from...

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;